Apellis Pharmaceuticals chief development officer sells $8,207 in stock

WALTHAM, MA—Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the company. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.36x, indicating ample resources to meet short-term obligations. According to a filing submitted to the Securities and Exchange Commission, Eisele sold 278 shares of common stock on January 29, 2025, at an average price of $29.5236 per share. The total value of the transaction amounted to $8,207.

Following the sale, Eisele retains a direct ownership of 55,312 shares in the company. The sale was conducted to cover tax withholding obligations related to the release of Restricted Stock Units on January 28, 2025, as noted in the filing.

In other recent news, Apellis Pharmaceuticals has experienced several significant developments. The company reported full-year 2024 U.S. net product revenues of approximately $709 million, marking a growth trajectory of 162% over the last twelve months. This performance was largely driven by the company’s lead products, SYFOVRE® and EMPAVELI®, which generated $611 million and $98 million in net revenues respectively.

Apellis also received approval from the Therapeutic Goods Administration (TGA) of Australia for SYFOVRE, the first treatment for geographic atrophy (GA) in the country. Despite this, Mizuho (NYSE:MFG) Securities maintained its Neutral rating on Apellis with a stable price target of $30.00, citing a modest total market opportunity for GA in Australia.

Analysts from firms such as Jefferies, RBC Capital Markets, and Morgan Stanley (NYSE:MS) provided insights into the company’s performance, with Goldman Sachs revising its rating for Apellis from Buy to Neutral. The company also announced organizational changes, including the appointment of David Acheson as Executive Vice President of Commercial. These are recent developments for Apellis Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.